Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: New drug developments for patients with metastatic soft tissue sarcoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This article was retracted on 28 February 2012

Abstract

For the subgroup of patients with inoperable gastrointestinal stromal tumors, progress has been made by the rapid development and approval of the targeted therapy imatinib mesylate. Small round cell sarcomas (SRCT), such as Ewing/primitive neuroectodermal tumor, desmoplastic SRCT, and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies that are treated with multimodality dose-intensive neoadjuvant protocols regardless of size or overt metastatic disease. However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Patel SR: New agents in the treatment of soft-tissue sarcomas. Expert Opin Investig Drugs 2000, 9:1545–1551.

    Article  PubMed  CAS  Google Scholar 

  2. Patel SR, Chu P, Vadhan-Raj S: Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicinbased chemotherapy. Proc Am Assoc Cancer Res 1997, 38:7.

    Google Scholar 

  3. Bertuzzi A, Castagna L, Nozza A, et al.: High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002, 20:2181–2188. This article deals with dose-intensified chemotherapy in adult patients with small round-cell tumors, demonstrating clinical as well as molecular findings in a special disease.

    Article  PubMed  CAS  Google Scholar 

  4. Kushner BH, LaQuaglia MP, Wollner N, et al.: Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996, 14:1526–1531.

    PubMed  CAS  Google Scholar 

  5. Borden EC, Amato DA, Rosenbaum C, et al.: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987, 5:840–850.

    PubMed  CAS  Google Scholar 

  6. Lopez M, Vici P, Di Lauro L, Carpano S: Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 2002, 20:1329–1334.

    Article  PubMed  CAS  Google Scholar 

  7. Cure H, Krakowski I, Adenis A, et al.: Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 1998, 34:422–423.

    Article  PubMed  CAS  Google Scholar 

  8. Bramwell VH, Anderson D, Charette ML: Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003, CD003293. This interesting study summarizes data regarding the palliative treatment of adult-type sarcomas.

  9. Benjamin RS, Legha SS, Patel SR, Nicaise C: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993, 31(Suppl 2):S174-S179.

    Google Scholar 

  10. Gottlieb JA, Benjamin RS, Baker LH, et al.: Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976, 60:199–203.

    PubMed  CAS  Google Scholar 

  11. Balcerzak SP, Benedetti J, Weiss GR, Natale RB: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 1995, 76:2248–2252.

    Article  PubMed  CAS  Google Scholar 

  12. Gallup DG, Blessing JA, Andersen W, Morgan MA: Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2003, 89:48–51.

    Article  PubMed  CAS  Google Scholar 

  13. van Hoesel QG, Verweij J, Catimel G, et al.: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994, 5:539–542.

    PubMed  Google Scholar 

  14. Kostler WJ, Brodowicz T, Attems Y, et al.: Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001, 12:1281–1288.

    Article  PubMed  CAS  Google Scholar 

  15. Edmonson JH, Ebbert LP, Nascimento AG, et al.: Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996, 19:574–576.

    Article  PubMed  CAS  Google Scholar 

  16. Verweij J, Lee SM, Ruka W et al.: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2081–2086.

    PubMed  CAS  Google Scholar 

  17. Okuno S, Geyer SM, Maples WJ, et al.: Phase 2 study of epothilone B analog (BMS-247550) in soft tissue sarcomas: an interim report [abstract 1645]. Proc ASCO 2002, 21:412a.

    Google Scholar 

  18. Casanova M, Ferrari A, Spreafico F, et al.: Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002, 94:3263–3268.

    Article  PubMed  CAS  Google Scholar 

  19. Fidias P, Demetri GD, Harmon D: Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner’s Cancercare study [abstract]. Proc ASCO 1998, 17:1977.

    Google Scholar 

  20. Spath-Schwalbe E, Genvresse I, Koschuth A, et al.: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000, 11:325–329.

    Article  PubMed  CAS  Google Scholar 

  21. Svancarova L, Blay JY, Judson IR, et al.: Gemcitabine in advanced adult soft-tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38:556–559.

    Article  PubMed  CAS  Google Scholar 

  22. Okuno S, Edmonson J, Mahoney M, et al.: Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002, 94:3225–3229.

    Article  PubMed  CAS  Google Scholar 

  23. Patel SR, Gandhi V, Jenkins J, et al.: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001, 19:3483–3489.

    PubMed  CAS  Google Scholar 

  24. Okuno S, Ryan LM, Edmonson JH, et al.: Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003, 97:1969–1973.

    Article  PubMed  CAS  Google Scholar 

  25. Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progressionfree rate as the principal end-point for phase II trials in softtissue sarcomas. Eur J Cancer 2002, 38:543–549. This is an excellent overview regarding statistical considerations and valid endpoints for phase II trials focusing particularly on soft tissue sarcomas.

    Article  PubMed  Google Scholar 

  26. Hartmann JT, Oechsle K, Huober J, et al.: An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated advanced soft tissue sarcoma. J Cancer Res Clin Oncol 2004, 130:S192 (abstract PO878).

    Article  Google Scholar 

  27. Amodio A, Carpano S, Manfredi C, et al.: [Gemcitabine in advanced stage soft tissue sarcoma: a phase II study]. Clin Ter 1999, 150:17–20.

    PubMed  CAS  Google Scholar 

  28. Blumgart LH, Espat N, Fong Y, Jarnagin WR: Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients with advanced sarcomas: a Mayo Cancer Center study [abstract]. Proc ASCO 2000, 19:50.

    Google Scholar 

  29. Delaloge S, Yovine A, Taamma A, et al.: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol 2001, 19:1248–1255.

    PubMed  CAS  Google Scholar 

  30. Demetri GD: ET-743: The US experience in sarcomas of soft tissues. Anticancer Drugs 2002, 13(Suppl 1):S7-S9.

    PubMed  CAS  Google Scholar 

  31. Yovine A, Riofrio M, Blay JY, et al.: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004, 22:890–899.

    Article  PubMed  CAS  Google Scholar 

  32. Garcia-Carbonero R, Supko JG, Manola J, et al.: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004, 22:1480–1490.

    Article  PubMed  CAS  Google Scholar 

  33. Leahy MG, Blay JY, le Cesne A, et al.: EORTC 62011: Phase II trial of brostallicin for soft tissue sarcoma. Presented at CTOS 9th Annual Meeting, Barcelona Spain, November 6–8, 2003, (46, abstract 94)

  34. Hartmann JT, Oechsle K, Mayer F, et al.: Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 2003, 23:1899–1901.

    PubMed  CAS  Google Scholar 

  35. Kollmannsberger C, Brugger W, Hartmann JT, et al.: Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999, 10:453–456.

    Article  PubMed  CAS  Google Scholar 

  36. Blomqvist C, Wiklund T, Pajunen M, et al.: Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995, 36:263–265.

    Article  PubMed  CAS  Google Scholar 

  37. Stevens MF, Hickman JA, Stone R, et al.: Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984, 27:196–201.

    Article  PubMed  CAS  Google Scholar 

  38. Woll PJ, Judson I, Lee SM, et al.: Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999, 35:410–412.

    Article  PubMed  CAS  Google Scholar 

  39. Trent JC, Beach J, Burgess MA, et al.: A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003, 98:2693–2699.

    Article  PubMed  CAS  Google Scholar 

  40. Bramwell VH, Eisenhauer EA, Blackstein M, et al.: Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995, 6:847–849.

    PubMed  CAS  Google Scholar 

  41. Budd GT, Rankin C, Hutchins LF, et al.: Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Invest New Drugs 2002, 20:129–132.

    Article  PubMed  CAS  Google Scholar 

  42. Reichardt P, Oechsle K, Pink D, et al.: An open label, noncomparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003, 21:481–486.

    Article  PubMed  CAS  Google Scholar 

  43. Saylors RL, III, Stine KC, Sullivan J, et al.: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001, 19:3463–3469.

    PubMed  CAS  Google Scholar 

  44. Hosono A, Makimoto A, Kawamoto H, et al.: A retrospective analysis in safety and efficacy of protracted administration of irinotecan for patients with small round cell sarcomas relapsed after stem cell transplantation (SCT) [abstract 3269]. Proc ASCO 2003, 22:813.

    Google Scholar 

  45. Pappo AS, Lyden E, Breitfeld PP, et al.: Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children’s Oncology Group (COG) [abstract 1570]. Proc ASCO 2002, 21:393.

    Google Scholar 

  46. De Angelo D, Naujoks R, Manola J, et al.: Phase II study of Irinotecan (CPT-11) in relapsed or refractory soft tissue sarcoma (STS) [abstract]. Proc ASCO 2000, 19:2186.

    Google Scholar 

  47. Wall ME, Wani MC, Natschke SM, Nicholas AW: Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J Med Chem 1986, 29:1553–1555.

    Article  PubMed  CAS  Google Scholar 

  48. Hensley ML, Maki R, Venkatraman E, et al.: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002, 20:2824–2831. This phase II trial provides evidence that gemcitabine and docetaxel are acting synergistically in leiomyosarcoma, whereas both drugs have limited efficacy given as single agents.

    Article  PubMed  CAS  Google Scholar 

  49. Pivot X, Chevreau C, Cupissol D, et al.: Phase II trial of paclitaxelepirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 2002, 25:561–564.

    Article  PubMed  Google Scholar 

  50. Raney RB, Anderson JR, Barr FG, et al.: Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001, 23:215–220.

    Article  PubMed  CAS  Google Scholar 

  51. Casanova M, Ferrari A, Bisogno G, et al.: Vinorelbine and lowdose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004, 101:1664–1671.

    Article  PubMed  CAS  Google Scholar 

  52. Tolcher AW, Eckhardt SG, Kuhn J, et al.: Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001, 19:2937–2947.

    PubMed  CAS  Google Scholar 

  53. Bramwell VH, Morris D, Ernst DS, et al.: Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracyclineresistant advanced soft tissue sarcoma. Clin Cancer Res 2002, 8:383–393.

    PubMed  CAS  Google Scholar 

  54. Li W, Fan J, Bertino JR: Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridolmediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001, 61:2579–2582.

    PubMed  CAS  Google Scholar 

  55. Tomek S, Koestler W, Horak P, et al.: Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003, 39:1318–1329.

    Article  PubMed  CAS  Google Scholar 

  56. Fata F, O’Reilly E, Ilson D, et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86:2034–2037.

    Article  PubMed  CAS  Google Scholar 

  57. Patel SR, Beach J, Papadopoulos N, et al.: Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced softtissue sarcomas. Cancer 2003, 97:2348–2852.

    Article  Google Scholar 

  58. Blay JY, Judson I, Rodenhuis S, et al.: Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999, 10:873–877.

    Article  PubMed  CAS  Google Scholar 

  59. Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005, 65:167–278.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology/Immunology/Rheumatology, UKT-Medical Center II, Eberhard-Karls-University Tuebingen, Otfried-Mueller-Str. 10, 72076, Tuebingen, Germany

    Jörg Thomas Hartmann MD & Shreyaskumar Patel MD

Authors
  1. Jörg Thomas Hartmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shreyaskumar Patel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

A retraction note to this article is available at http://dx.doi.org/10.1007/s11912-012-0228-x.

This article has been retracted due to significant overlap with an article previously published in a different journal (Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005, 65:167–178.)

An erratum to this article is available at http://dx.doi.org/10.1007/s11912-012-0228-x.

About this article

Cite this article

Hartmann, J.T., Patel, S. RETRACTED ARTICLE: New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep 7, 300–306 (2005). https://doi.org/10.1007/s11912-005-0054-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0054-5

Keywords

Search

Navigation